Coping Compliance and Adjustment in Adolescents With Cystic Fibrosis
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
OVERVIEW: We anticipate that the data we collect will help us better understand some of the factors associated with improved coping, treatment compliance, and emotional adjustment, which, in turn, may suggest possible interventions to improve compliance, emotional adjustment, and general physical health. Specific hypotheses include the following:
- Subjects who score high on measures of positive coping will have greater levels of treatment compliance and psychological well-being.
- Subjects who score high on measures of negative coping will have lower levels of treatment compliance and psychological well-being.
- Subjects who score high on measures of positive religious coping will have greater levels of treatment compliance and psychological well being.
- Subjects who score high on measures of negative religious coping will have lower levels of treatment compliance and psychological well-being.
- Subjects who score high on measures of internal locus of control will have higher levels of treatment compliance and psychological well-being compared to subjects who score low on measures of internal locus of control.
- Subjects who score high on measures of treatment compliance will have higher levels of physical health.
- We do not anticipate a positive correlation between positive coping mechanisms and general physical health; however, subjects who score high on measures of negative coping may have lower levels of general physical health (e.g., lower PFTs, increased rates and lengths of hospitalizations) probably due to third variables (e.g., if someone uses denial as a coping mechanism, it may lead to poor treatment compliance, which may lead to declines in physical health).
- Anecdotal evidence suggests that parental education may be positively correlated with treatment compliance, but this has not been evaluated. Likewise, anecdotal evidence suggest that marital status may be correlated with treatment compliance (probably because of third variables, e.g., if, as much research suggests, divorce is related to lower SES and fewer social supports, these factors may in turn interfere with treatment compliance). Two questions on the demographic sheet will allow us to explore whether or not this may be worth exploring further.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Akron Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- cystic fibrosis age 13-19 yrs
Exclusion Criteria:
- acutely ill
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
1
Adolescents with CF.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Multiple measures of coping strategies in adolescents with cystic fibrosis.
Time Frame: Single visit
|
Single visit
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Coping startegies will be correlated with measures of clinical illness.
Time Frame: Single visit
|
Single visit
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nathan C Kraynack, MD, Akron Children's Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- COPING1424
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
NCT03273959UnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With Exacerbation
-
NCT07223255RecruitingCystic Fibrosis (CF) | Cystic Fibrosis Gastrointestinal Disease
-
NCT07616375RecruitingNon-cystic Fibrosis Bronchiectasis
-
NCT07245407RecruitingNon-cystic Fibrosis Bronchiectasis
-
NCT07484607RecruitingCystic Fibrosis (CF) | Cystic Fibrosis Pulmonary Exacerbation
-
NCT07289464RecruitingNon-cystic Fibrosis Bronchiectasis
-
NCT03939065TerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children
-
NCT04602468Active, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver Disease
-
NCT06084468Active, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease
-
NCT06940531RecruitingCystic Fibrosis (CF) | Cystic Fibrosis Pulmonary Exacerbation